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Abstract
Background: The natural history of ocular Chlamydia trachomatis infections in endemic communities has not been well
characterised and is an important determinant of the effectiveness of different mass treatment strategies to prevent
blindness due to trachoma.
Methodology/Principal Findings: A multistate hidden Markov model was fitted to data on infection and active disease
from 256 untreated villagers in The Gambia who were examined every 2 weeks over a 6-month period. Parameters defining
the natural history of trachoma were estimated, and associations between these parameters, demographic and baseline
immune measurements examined. The median incubation period following infection was estimated at 17 days (95%
confidence interval: 11–28). Disease persisted for longer than infection (median 21 (15–32) weeks) versus 17 (12–24) weeks),
with an estimated median duration of post-infection inflammation of 5 (3–8) weeks. The duration of active disease showed a
significant decline with age even after accounting for lower rates of re-infection and disease at older ages (p = 0.004).
Measurements of levels of baseline IgA to epitopes in the major outer membrane protein of Chlamydia trachomatis were
not significantly correlated with protection or more rapid clearance of infection.
Conclusions: The average duration of infection with Chlamydia trachomatis especially at younger ages is long. This
contributes to the persistence and gradual return of trachoma after community-wide treatment with antibiotics.
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Introduction
The scarring and blindness that result from repeated infection of
the eye with Chlamydia trachomatis represent a significant public
health burden in some of the poorest parts of the world [1].
Community-wide treatment with antibiotics can significantly
reduce the prevalence of infection and active inflammatory disease
[2–5] and is central to current efforts led by the World Health
Organisation to eliminate blindness due to trachoma by 2020. The
effectiveness of different mass treatment strategies depends on
several key parameters describing the natural history of trachoma.
For example, the duration of infection determines the rate of
return of infection after mass treatment and therefore the
frequency of treatment rounds needed to achieve a sustained
reduction in the prevalence of infection and disease [6]. The
development of an effective vaccine against trachoma also requires
a better understanding of the natural history of infection, how this
changes following prior exposure to infections and the immune
mechanisms that effect these changes [7]. The immune response to
infection is finely balanced between protective and pathologic
components and indeed some early vaccine candidates appeared
to increase disease among younger children [8]. Animal models of
ocular and genital Chlamydia infections have been useful in
examining the immune response to infection [9–11]. However,
inference from animal models is not always appropriate, since
elements of the immune response may be host-species specific.
Some information on the progression of infection and inflam-
matory disease comes from early experimental inoculations of the
eyes of volunteers [12–16]. However, these studies have been
limited by the number of subjects and by the laboratory technology
available, and do not provide information about the development
of immunity and changes in disease natural history following
multiple exposures to infection, such as occurs in endemic
communities. Longitudinal cohort studies in trachoma endemic
communities are therefore invaluable in providing estimates of the
natural history of trachoma and determining immune correlates of
protection against infection and disease. Cohort studies of genital
chlamydia have identified an important role for interferon-c in
protection against infection [17], and allowed the estimation of the
duration of genital infection in asymptomatic women in the
absence of antibiotic treatment [18]. However, the long intervals
between follow-up visits in this study, and the difficulty in excluding
reinfection, lead to considerable uncertainty. In addition genital
and ocular strains of C. trachomatis show significant differences that
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can alter their sensitivity to immune effectors, complicating
inference between these systems [19].
Here we present an analysis of a cohort study of ocular C.
trachomatis infection from an endemic community in the Gambia
with frequent (two-weekly) follow-up over 6 months [20]. We
estimated parameters describing the natural history of trachoma
and associations between these parameters and demographic
variables and baseline measurements of immunity. The analysis
used a multi-state Markov model that allows for re-infection
between follow-up visits and permits the sensitivity and specificity
of laboratory tests for chlamydia and clinical diagnosis to be
estimated.
Materials and Methods
Ethical approval
The original study received ethical approval from the joint
Gambia Government and Medical Research Council Ethics
Committee (SCC 508). All subjects gave oral informed consent
that was witnessed and signed by the witness following the
standard consent procedures at the time. The current study is an
analysis of this original study and did not involve gathering any
new information.
Data
Following a baseline survey 256 individuals from two Gambian
villages, Jali and Berending, were examined for clinical and
laboratory signs of infection every two weeks over a 6 month
period. These individuals were members of 20 households
randomly selected from all households in the baseline survey with
at least one active trachoma case and at least 3 members without
active trachoma. Members of the selected households not present
at baseline were included in the survey on their return and
thereafter. Clinical scoring of active trachoma was based on the
system of Dawson and colleagues [21], and conjunctival swabs
tested for the presence of chlamydial lipopolysaccharide antigen by
ELISA (IDEIA test, Dako, Copenhagen). Details of the study
cohort, clinical and laboratory tests and survival analysis of the
data are described elsewhere [20].
At baseline tear fluid IgA and IgG responses to epitopes of the
variable segments of the chlamydial major outer membrane
protein defined on the basis of their amino acid sequence were
measured using ELISA methods to assess antibody binding to
epitopic peptide segments conjugated to human serum albumin as
previously described [22].
A simple Markov model of trachoma infection and
disease
To begin with, we considered the cohort data on infection and
clinical diagnosis separately. In this case, incident infection (or
onset of disease) and the clearance of infection (or disease
resolution) in an individual is a simple two-state Markov process
with constant hazards l and n respectively over the period of
analysis (Figure 1A). A Markov process is one in which the future
state of the system depends only on the present state and not the
history of the system. Here we assumed active disease includes
mild, moderate and severe disease, which encompass both intense
trachoma (TI) and follicular trachoma (TF) in the simplified WHO
scoring system [23].
In each case, the Markov process can be characterized by the
transition intensity matrix
Q~
{l l
n {n
 
ð1Þ
where qrs describes the instantaneous hazard of moving from state r
to state s for r?s and qrs~{
X
r=i
qri for r= s [24]. If two
observations of an individual are separated by time t , then the
probability of observing a transition from r to s is described by the
transition probability matrix P with entries prs(t). This may be
calculated from the matrix exponential P(t) = exp(tQ), which, in the
case of this simple 2-state Markov process, is given by
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A more complex model of the natural history of infection
and disease
Where cohort studies include laboratory tests for infection in
addition to clinical diagnoses at follow-up visits it is possible to test
the fit of different models of disease natural history. In this case we
considered a four state Markov model, with each state corre-
sponding to whether an individual is infected and whether they
have active disease (Figure 1B). Using this approach, it was
possible to test the fit and estimate the parameters of different
models of disease natural history. For example, the ‘standard’
natural history summarised by Wright and Taylor [9], and
illustrated in Figure 1C, corresponds to a transition intensity
matrix
Q~
{l l 0 0
0 {c 0 c
n 0 {n 0
0 0 e {e
2
6664
3
7775 ð3Þ
where qrs describes the instantaneous hazard of moving from state r
to state s (with states given in Figure 1B). Note that we do not allow
instantaneous transitions that result in changes in both the
Author Summary
Trachoma is an infectious disease of the eye that causes
blindness in many of the poorest parts of the world. In this
paper, we use a novel statistical approach to estimate the
characteristics of this disease among people living in The
Gambia who were examined every 2 weeks over a 6-
month period. We found that the typical duration of
infection with Chlamydia trachomatis and of clinically
active disease were significantly longer than previously
estimated. We tested different hypotheses about the
natural history of trachoma that explain the relationship
between infection and disease observed in the field. We
also confirmed that disease lasts significantly longer
among young children under 5 years old compared with
older children and adults, even after accounting for high
rates of re-infection in this age group, consistent with the
development of immunity with age. The long duration of
infection, especially among younger children, contributes
to the persistence and gradual return of trachoma after
community-wide treatment with azithromycin. This implies
the need for high treatment coverage if infection is to be
eliminated from a community, even where the return of
infection after treatment is seen to be slow.
Trachoma Natural History in Humans
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infection and disease state, although over a longer period such
transitions may be observed, with the probability given by
P(t) = exp(tQ) as before.
Hidden Markov Models
Laboratory and clinical diagnoses are not without error. In the
case of enzyme immunoassay for chlamydial antigen the sensitivity
g and specificity s may be quite low. Observer error can also
compromise the sensitivity and specificity of clinical diagnosis,
although the magnitude of this effect is likely to be smaller. In
other words, the true status of each individual is ‘hidden’ and we
only observe the results of the laboratory tests and/or clinical
diagnoses. The relationship between the true status of an
individual and that observed is given by the emission matrix of
the hidden Markov model (HMM). In the two-state model
(Figure 1A) this is simply
E~
s 1{s
1{g g
 
ð4Þ
where esw is the probability an individual in state s has laboratory
result (or clinical diagnosis) w, and s is the specificity and g the
sensitivity of the laboratory test (or clinical diagnosis). If El is the
emission matrix for the infection process and Ec the emission
matrix for the disease process, then the emission matrix of the four
state model of trachoma natural history is given by the matrix
direct product EcﬂEl.
Likelihood of the hidden Markov model
Each individual in a cohort study may be clinically examined
and/or tested for infection on a number of occasions. We denote
the observation for individual i on the jth occasion by yij and the
time of observation by tij. The true (hidden) state of individual i is
given by xij. The number of times each individual is observed
during a study will depend on the frequency and success of follow-
up visits. We assume that these are independent of the underlying
infection or disease state of the individual.
The likelihood contribution of individual i can be written as a
matrix product, following MacDonald and Zucchini [25] and
Jackson [26],
Li~dTi1Ti2, . . .Tin1 ð5Þ
where d is a vector with the kth entry equal to the product of the
probability that individual i initially occupies state k, Pr(si1 = k) and
the probability of observation yi1 given that underlying state
Pr yi1jkð Þ ~eyi1k
 
, 1 is a column vector consisting of ones, n is the
number of observations for individual i and Tij is a matrix given by
Tij~P tij{ti, j{1
 
e yij
  ð6Þ
where e(y) = diag(e1y, e2y) or diag(e1y, e2y, e3y, e4y) for the 2-state and
4-state models respectively.
Estimating parameters
The transition hazards and sensitivity and specificity of the
laboratory tests (or clinical diagnoses) were estimated from the
data by finding the HMM with the maximum likelihood. We also
examined whether the transition hazards in the 2-state models
depended on covariates including age, sex and baseline immune
parameters, using a proportional hazards model, such that the
entries of the transition intensity matrix are given by
qrs Zð Þ~qrs exp bTrsZ
  ð7Þ
where brs is the vector of regression coefficients associated with a
vector of covariates Z for the transition from r to s [26,27]. We
assumed that covariates did not change over time and that the
sensitivity and specificity of the laboratory tests and clinical
diagnoses did not depend on age or change over time. In the 4-
state model the sensitivity and specificity of the laboratory tests and
clinical diagnoses were fixed at the estimates from the two-state
model and age was not considered as a covariate on transition
intensities.
The initial probability distribution for the ‘true’ underlying
states of individuals at the first observation (the probabilities
Pr(si1 = k) that make up d in equation (5)) was estimated by finding
the HMM with the maximum likelihood. This distribution was
Figure 1. Markov models of the natural history of active trachoma. A) A simple model of infection with a constant hazard of becoming
infected l or recovering from infection n. This same two-state model can be used to describe the process of the onset and resolution of inflammatory
disease. B) A four state model of infection and disease with states indexed from 1 to 4. In this case transition intensities for the infection and disease
processes are mutually dependent. For example, the probability of clearing infection depends on whether inflammatory disease is present. The
‘standard’ model of trachoma natural history corresponds to the solid arrows with transition parameters marked. This is illustrated in C), where time
runs from left to right and disease states are indicated at the top of the figure.
doi:10.1371/journal.pntd.0000341.g001
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allowed to depend on the covariates of the transition intensities (for
example, the baseline prevalence of infection and disease decline
with age). The dependence of the baseline infection or disease
status on covariates such as age was estimated using multinomial
logistic regression since the probabilities must sum to one (see [26]
for details).
Asymptotic estimates of the standard error of the estimates of Q,
E, d and b were obtained by inverting the Hessian matrix of the
maximized log-likelihood following the methods of Kalbfleisch and
Lawless [28]. Approximate confidence intervals about the
estimates are given assuming normality on the log-scale for Q
and b and on the logit scale for entries in E and d. Plots of the
likelihood as a function of pairs of parameter estimates were
examined to determine the appropriateness of this assumption.
Different (nested) models were compared using the likelihood ratio
statistic [24,29].
To maximise the likelihood and estimate confidence intervals
we used the freely available multi-state modelling (msm) package
written in the R programming language with the simulated
annealing optimization method [26].
Model fit
The ability of the 2-state HMM to describe the observed data
was assessed by simulating observations under the model for
infection and the model for active disease with parameters set to
their maximum likelihood estimates. For each individual in the
cohort 1000 simulated observations were produced based on the
reported examination times and with the initial state randomly
drawn from the probability distribution estimated from the data.
The number of transitions between infected and diseased states in
the simulations was then compared to the actual number observed.
Results
Duration of C. trachomatis infection and active
inflammatory disease
The estimated median duration of active trachoma (TI and TF)
was approximately 8 months among children 0–4 years old but with
broad 95% confidence intervals (Table 1). At older ages the estimated
duration of active disease declined to 18.8 weeks for children aged 5
to 14 years old, and to 7.0 weeks for older children and adults. The
duration of active disease in older children and adults was
significantly shorter than for children aged under 5 years
(p= 0.004). The hazard of developing active disease showed a
significant decline with age (likelihood ratio=5.4, p=0.005; Table 1).
The estimated duration and hazard of infection with C.
trachomatis show a similar pattern with age to that for disease.
The duration of infection in children aged 0–4 years was estimated
at 15.4 weeks, compared to 8.2 weeks for children aged 5–14 years
old and 7.6 weeks for older children and adults, although this
decline was non-significant (likelihood ratio = 2.2, p = 0.11). The
estimated duration of infection was shorter than the duration of
disease at all ages, suggesting persistence of disease for a period
after the clearance of infection. The hazard of infection showed a
significant decline with age (likelihood ratio = 3.2, p = 0.04).
The hazard of infection or developing active disease was not
found to depend on sex. The duration of infection was
independent of sex, but there was some evidence of a shorter
duration of active disease among males (p = 0.02).
Sensitivity and specificity of laboratory tests and clinical
diagnoses
The sensitivity and specificity of the laboratory tests and clinical
diagnoses to detect the underlying infection and disease states
predicted by the Markov model were estimated at the same time as
the duration of infection and disease (Table 1). The maximum
likelihood estimates of the sensitivity of the laboratory tests and
clinical diagnoses were well-defined and the likelihood surface was
consistent with the normality assumption used to generate
approximate confidence intervals (Figure 2).
Natural history of trachoma
The transition intensities of the four-state Markov model
corresponding to the ‘standard’ model of trachoma natural history
illustrated in Figure 1C were estimated from the data (Table 2).
The fit of this four-state model provided an estimate of the median
duration of the incubation period of about 2 weeks (95% CI: 11–
28 days), and of post-infection inflammatory disease of about 5
weeks (3.6 to 8.0 weeks) in addition to estimates of the duration of
infection and active disease.
The likelihood of a model that allows for inflammatory disease
(TI/TF) due to an immediate cause other than infection with C.
trachomatis (transition path 1R3R1 in Figure 1B) was significantly
better than the standard model (likelihood ratio = 3.6, p = 0.002).
The estimated hazard of active disease in uninfected individuals is
smaller (0.18 per year) than the hazard of infection with C.
trachomatis and subsequent disease (0.31 per year). A model that
allowed for asymptomatic infection also gave an improved fit
compared with the standard model (likelihood ratio = 3.3,
p = 0.005). The estimates of the parameters defining the natural
Table 1. Duration of trachoma infection and disease, and sensitivity and specificity of laboratory tests and clinical diagnoses (with
approximate 95% confidence intervals).
Sensitivity (%) Specificity (%) Age (years) Median duration (weeks)
Hazard of infection/disease (per
year)
Disease 97 (95–98) 93 (90–95)
0–4 36.1 (17.7–73.5) 1.4 (0.73–2.6)
5–14 18.8 (11.5–30.7) 0.68 (0.38–1.2)
15+ 7.0 (2.6–19.2) 0.35 (0.15–0.83)
Infection 77 (70–82) 94 (92–96)
0–4 15.4 (8.3–28.6) 1.3 (0.6–2.6)
5–14 8.2 (5.3–12.6) 0.58 (0.24–1.4)
15+ 7.6 (2.2–26.9) 0.072 (0.0036–1.4)
doi:10.1371/journal.pntd.0000341.t001
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history of trachoma were similar in both the standard model and a
modified model, in which asymptomatic infections and inflamma-
tory disease without detectable C. trachomatis infection occur
(Table 2). Further extending the model of natural history to
include the possibility of repeated infection leading to sustained
active disease (transition path 4R3R4) significantly improved the
fit of the model compared with this modified model (likelihood
ratio = 8.2, p,0.001; Table 2).
The estimated probability that an individual diagnosed with
active disease was infected with C. trachomatis (positive predictive
value) was 71% based on the fit of the standard model of natural
history, 61% in the modified model and 65% in the modified
model with active disease sustained by repeat infection. The
estimated probability that an individual diagnosed without active
trachoma was uninfected (negative predictive value) was 91%,
90% and 91% based on the fit of these models respectively.
Figure 2. Likelihood of the hidden Markov model for active disease or infection, for different values of the median duration and
test sensitivity plotted about the maximum likelihood estimate. The model for active disease is shown in A) and infection in B). In each plot
the duration of disease or infection is plotted on a log-scale and sensitivity on the logit scale.
doi:10.1371/journal.pntd.0000341.g002
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The effect of baseline immunological parameters on
trachoma natural history
Elevated levels of tear IgA to previously defined epitopes [22] in
the VS1 and VS2 domains of serotypes A and B respectively were
found among 55% and 17% of the cohort at baseline (elevated IgA
was defined as those individuals with .0.1 adjusted optical density
units, consistent with earlier studies [30]). However, elevated IgA
was not found to correlate with protection against infection with
these subtypes (relative rate (RR) of infection in the 4-state model
of 45 (95% CI: 0.21–9670) and 0.92 (0.05–15.5) respectively).
Similarly, IgA levels to the same epitopes did not show a significant
association with the rate of clearance of infection (transition from 4
to 3).
Model fit
Simulations under the maximum likelihood HMMs of the
infection and disease process resulted in a similar number of
transitions to that observed in the cohort (Table 3).
Discussion
The ‘standard’ model of the natural history of trachoma
illustrated in Figure 1 is based largely on observations following
inoculation of cynomolgus monkeys with C. trachomatis and early
experimental inoculations of a small number of volunteers [9,12–
16]. This paper presents the first test of this model in an endemic
community.
After ocular infection with C. trachomatis, active inflammatory
disease develops rapidly and persists for some time after infection
has been cleared (Figure 3). The estimate of the inflammatory
period after disease clearance (Table 2) is consistent with the
observation in a clinical trial of a median duration of active
trachoma of about 5 weeks after treatment of infection with
azithromycin [31]. The persistence of disease predicts a significant
prevalence of active disease without detectable Chlamydia organ-
isms, in agreement with observations from cross-sectional studies
[32–36]. Thus active disease is not strongly predictive of infection
(positive predictive value 61%–71%) and so targeting diseased
individuals for treatment will result in a significant number of
unnecessary treatments (although less than community-wide
treatment).
The short estimated incubation period (Table 2) is in reasonable
agreement with an average observed incubation period of 6 days
(range 2–13 days) for volunteers inoculated with C. trachomatis [14].
This suggests that few individuals will have infection detectable by
enzyme immunoassay without active disease. This remains the
case even after allowing for asymptomatic infections in the
modified model, which finds the absence of active disease is
strongly predictive of the absence of infection (negative predictive
value 90%). This may be helpful in excluding communities with a
low prevalence of active disease from treatment. Recent studies
support this conclusion, describing a high prevalence of active
disease among individuals with active (high-load) infections based
on quantitative PCR for chlamydial RNA or DNA [32,37,38].
This clarifies the interpretation of earlier studies that used
qualitative PCR to detect chlamydial DNA and found conjunctival
swabs from disease-free individuals often tested positive [33–36].
Whilst some of these positive tests may be early infections
prodromal to inflammatory disease, frequent detection of low
levels of chlamydial DNA may also reflect inoculation of the eye
with non-viable organisms or cross-contamination during exam-
ination [9,37].The presence of infection without a diagnosis of
active disease may also occasionally reflect problems with clinical
grading.
Overall, infection with Chlamydia trachomatis is estimated to last a
median of about 17 weeks and active disease (TI/TF) somewhat
longer at about 21 weeks in the standard model (Table 2). These
estimates are longer than previously estimated from the same
cohort study, since they allow for the possibility of false negative
and false positive tests that can break up long runs of positive or
Table 2. Parameter estimates for different models of trachoma natural history using the best estimates of the sensitivity and
specificity of tests of infection and disease.
Stage (Markov model state
label in Figure 1B) Median duration and approximate 95% confidence intervals Time units
Standard model Log-
likelihood=1743.1
Modified model Log-
likelihood=1736.1
Modified model with active
disease sustained by repeat
infection Log-
likelihood=1727.9
Infection (2 & 4) 17.2 (13.7, 23.0) 18.2 (13.9, 26.2) 14.4 (10.3, 20.6) weeks
Active disease (4 & 3) 21.1 (16.8, 28.4) 23.2 (18.9, 32.5) 26.9 (19.9, 38.4) weeks
Incubation (2) 17.4 (10.9, 27.7) 15.4 (6.9, 32.8) 20.0 (10.5, 34.8) days
Post-infection inflammation (3) 5.4 (3.6, 8.0) 5.1 (3.4, 7.7) 3.6 (2.2, 5.5) weeks
doi:10.1371/journal.pntd.0000341.t002
Table 3. Number of transitions in disease and infection status
observed in actual cohort and simulated data.
Transition Data Number*
From\To No Disease Diseased
No disease Observed 1320 112
Simulated 1378 (1279, 1465) 105 (87, 125)
Diseased Observed 112 513
Simulated 108 (91, 129) 465 (386, 556)
From\To Uninfected Infected
Uninfected Observed 1415 162
Simulated 1407 (1325, 1489) 183 (159, 189)
Infected Observed 176 253
Simulated 167 (143, 189) 248 (194, 305)
*median, 2.5th and 97.5th percentiles of ranked counts are shown for
simulations.
doi:10.1371/journal.pntd.0000341.t003
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negative tests or diagnoses. Traditional survival analysis does not
allow for this process, leading to an under-estimate of the duration
of infection and disease, and an over-estimate of the hazard of
infection (this can be illustrated by fitting the Markov model with
100% test sensitivity and specificity; Table S1). The longer
duration of infection compared to previous estimates from the
same dataset [20] means that infection will emerge more slowly
after mass treatment than expected from baseline prevalence if the
duration of infection were shorter. However, it also means
infection can persist at low levels, highlighting the importance of
achieving high coverage during community-wide antibiotic
treatment. Slow rates of return of infection and in some cases
local elimination have been observed in low to moderate
prevalence communities following treatment [2,4,39].
The estimated duration of ocular Chlamydia trachomatis infection
is shorter than that found for female genital infections, where
infection typically last for a median of about one year [18,40–42]
(although re-infection between infrequent follow-up visits could
not be excluded in these studies). This may be the result of the
better ability of C. trachomatis to persist in the genital tract
compared with the conjunctiva.
Previous analysis of the cohort data examined in this study
found a significant decline in the duration of infection and disease
with age suggesting the importance of acquired immunity to
trachoma [20]. It has been suggested that the apparent decline in
duration with age may be the result of less frequent re-infection
between follow-up visits rather than evidence for an acquired
immune response [43]. However, in the present analysis, this
decline remains after accounting for re-infection and misclassifi-
cation, and is statistically significant in the case of active disease
(Table 1). This confirms the importance of acquired immunity at
least in the rate of resolution of active inflammatory disease. The
estimated hazard of infection and disease also decline with age,
consistent with changing exposure, hygiene practices and perhaps
acquired immunity to re-infection.
Elevated levels of IgA at baseline to epitopes in the VS1 and
VS2 domains of the major outer membrane protein were not
found to be associated with a protective effect against infection
with Chlamydia or with the speed with which infection was cleared.
This is in agreement with an earlier follow-up study in the same
population [30]. This may be the result of low statistical power or
the potential importance of other epitopes and immune mecha-
nisms in protection against infection and disease resolution [44].
Extending the standard model of trachoma natural history to
include asymptomatic infection and inflammatory disease in the
absence of detectable C. trachomatis infection provides a signifi-
cantly better fit to the observed data. Including the possibility that
active disease is sustained by repeated infection before the
resolution of disease further improves the fit of the model. The
estimates of the key parameters describing the natural history of
trachoma are reasonably robust to these extensions (Table 2).
Allowing for repeated infection and sustained active disease
increases the median duration of active disease, and decreases the
median duration of infection and post-infection inflammation. The
presence of active disease without C. trachomatis infection lowers the
positive predictive value of disease for infection. Inflammatory
disease in the absence of C. trachomatis may be the result of
infection with other bacterial pathogens or mechanical irritation
due to inturned lashes or a dry ocular surface among individuals
with earlier trachoma disease [45].
The estimated sensitivity (77%) and specificity (94%) of the
chlamydial lipopolysaccharide immunoassay to detect the infec-
tion state predicted by the Markov model are similar to, but
somewhat lower than, estimates of 84% and 99% respectively,
based on comparison of a fixed (dipstick) version of the assay with
PCR results in Tanzania [46]. This may reflect differences in the
handling of samples and the potential for cross-contamination, or
perhaps the use of a PCR-based test as the gold standard for the
dipstick assay [46], where false positive PCR results could raise the
estimated specificity of the assay.
Figure 3. Development of active disease (TF/TI) after ocular infection with C. trachomatis estimated from cohort data under the
standard model of trachoma natural history. The fraction of individuals who remain infected (solid line) or who have active disease (dashed
line) is plotted against the time since infection. The shaded areas highlight individuals with incubating infections or post-infection inflammation
(active disease). The parameter estimates are from Table 2.
doi:10.1371/journal.pntd.0000341.g003
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The estimated sensitivity (97%) and specificity (93%) of the
clinical diagnosis to detect the disease state predicted by the
Markov model are greater than for the immunoassay for infection.
This agrees with the low estimated observer error in this cohort
study of about 2%, based on a repeat examination of 123
individuals on the same day by the same examiner [20]. The
observer error does not account for transient inflammatory disease
that might result from causes other than C. trachomatis infection,
and indeed the estimated specificity of clinical diagnosis is lower
(93%) than that predicted by an observer error of just 2%.
The constant transition intensities of the Markov model imply
that the time spent in each state follows the exponential
distribution, and thus that the probability distribution describing
the time from entering one state to exiting a subsequent state is a
sum of exponential variables (i.e. a gamma distribution). This
distribution is quite flexible and is illustrated for the infectious and
diseased states in the 4-state model in Figure 3. The resulting
estimate of the duration of active disease is in agreement with the
estimate based on examining disease in isolation (Table 1). The
average duration of infection estimated in the 4-state model is
slightly longer than in the 2-state model, which may indicate the
role of active disease in providing information about the presence
of infection, in addition to the laboratory test, in the 4-state model.
The Markov assumption seems reasonable, since simulations of
the infection and disease process result in similar numbers of state
transitions to that observed in the cohort data (Table 3).
Further cohort studies of trachoma are required to allow the
identification of the components of protective immunity against
ocular Chlamydia trachomatis. The methods described in this paper,
based on hidden Markov models, allow for continued exposure to
infection and provide estimates of the sensitivity and specificity of
clinical and diagnostic tests. These methods are well suited to the
analyses of future cohort studies of trachoma.
Supporting Information
Table S1 Duration of trachoma infection and disease, assuming
100% sensitivity and specificity of laboratory tests and clinical
diagnoses (with 95% confidence intervals)
Found at: doi:10.1371/journal.pntd.0000341.s001 (0.03 MB
DOC)
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